Talking about the company's future plans, Becton Dickinson's Asia Pacific region business director Laureen F Higgins told The Financial Express, "We are in talks with Shanta Biotech, Bharat Biotech and Wockhardt for co-marketing. Many vaccine manufacturers have shown interest in Uniject, a pre-filled injection device. So they will give us the vaccine to pre-fill it and then together we will co-market the product." With the Indian medical devices market growing at 20 to 25 per cent, BD India plans rapid expansion of its business. BD will be offering the Indian government various medical equipment, which can prove to be cost effective, safe, non-reusable, and easy to dispose off, for a number of immunisation, vaccination programmes underway and government-run hospitals. The company has a state-of-the-art manufacturing plant near Gurgaon and had a turnover of $30 million for the last financial year ended September 2000,The latest that BD has to offer to the consumers in India, is the BD Solo Shot FX, an auto disposable syringe, Unijet, a pre-filled injection device, and vacutainer, a blood testing instrument.

BD India's managing director CD Sharma said, "Prior to Indian operations, the company had to pay high import duties, sometimes about 120 per cent, making the products less competitive, in terms of prices and quality. Before the Bawal plant came up, we could not study and make available the needs and demands of the domestic market.